glp-1 novo Nordisk Finds Medicare Patients Prefer Pill Over Shot for Weight Loss Novo Nordisk cautiously optimistic on

While taste changes during treatment with GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists are generally benign and self-limiting, certain situations warrant medical evaluation to rule out complications or alternative diagnoses

They are often combined for a synergistic effect

The TGA described the eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), as a rare but serious condition that may result in permanent visual impairment, including blindness and no treatment has been shown to improve visual acuity outcomes

Studies show benefits in experimental models of ulcers, inflammatory bowel disease, and leaky gut by modulating the gutbrainimmune axis